Cancer immunotherapy: Pros, cons and beyond - 11/02/20
pages | 11 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Tumor immunotherapy mainly includes ICIs, cellular immunotherapy, exosome immunotherapy, and other novel therapies. |
• | The therapeutic effect of immunotherapy is affected by immune microenvironment, intestinal bacteria and TMB. |
• | Drug resistance and adverse reactions are challenges in the development of immunotherapy. |
• | The future direction of immunotherapy is mainly to reduce side effects and improve the targeting of therapy. |
Abstract |
Cancer immunotherapy is an innovative treatment for tumors today. In various experiments and clinical studies, it has been found that immunotherapy does have incomparable advantages over traditional anti-tumor therapy, which can prolong progression-free survival (PFS) and overall survival (OS). However, immunotherapy has obvious complexity and uncertainty. Immunotherapy may also cause severe adverse reactions due to an overactive immune system. More effective and fewer adverse reactions immunological checkpoints are still under further exploration. This review gives an overview of recent developments in immunotherapy and indicates a new direction of tumor treatment through analyzing the pros and cons of immunotherapy coupled with keeping a close watch on the development trend of the immunotherapy future.
Le texte complet de cet article est disponible en PDF.Abbreviations : ACI, aeTSAs, APCs, ADCC, BCMA, BiTE, bTMB, CIK, CAR-T, CRS, CyTOF, CAF, CTL, DC, DAMPs, hTERT, HPD, iUPD, imRECIST, ICIs, ITH, irAE, KARs, KIRs, LAK, LTSCP, MAK, MDSCs, MM, MSI, MSI-H, mTSAs, MHC, NKC, OS, PD, PFS, RECIST, TIL, Tregs, TCR-T, TME, TMB, TAMs, TAA, TAPC, TGR
Keywords : Cancer immunotherapy, Immune checkpoint inhibitors, Tumor microenvironment, CAR-T, PD-1
Plan
Vol 124
Article 109821- avril 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?